Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia - OncLive
5/27/2022 12:00:00 AM2 years 11 months ago
by Chris Ryan
by Chris Ryan
The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.
The BTK inhibitor zanubrutinib (Brukinsa) has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma (MCL), relapsed or refractory marginal zone lym… [+6722 chars]
full article...